|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 07, 2017 ) According to the report, the Global Industry for nuclear medicine Radiopharmaceuticals is published by the Market data forecast. The Industry has been estimated at $4500 million in 2015 and is expected to reach $8440 million by 2020, growing at a CAGR of 13.4%. Nuclear medicine falls under the field of Molecular imaging, which involves usage of minute amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease.
Browse Industry data tables and in-depth TOC of the Global nuclear medicine Radiopharmaceuticals Industry to 2021 @ http://www.marketdataforecast.com/market-reports/global-nuclear-medicine-radiopharmaceuticals-market-130/
Increasing incidence of cancer and cardiac ailments, immense technological advancements, increasing demand SPECT and PET applications and also the growing public awareness for healthcare are fuelling the Industry growth for Radiopharmaceuticals.Further, Integration of X ray tomography (CT) into SPECT has recently emerged as a excellent diagnostic tool in medical imaging and is considered to be a driving factor for the growth of the Industry. Strict regulatory framework which pose as a hurdle to translational research and clinical investigations and reimbursement issues are blocking the growth of the Industry. In addition, shorter half-life of radiopharmaceuticals and competition from orthodox diagnostic procedures are also restraining the global nuclear medicine Radioisotopes Industry.
Download Free Sample Report @ http://www.marketdataforecast.com/market-reports/global-nuclear-medicine-radiopharmaceuticals-market-130/request-sample
The Industry of radiopharmaceuticals is dominated by Diagnostic radioisotopes and Therapeutic radioisotopes. Diagnostic radioisotope Industry basically covers SPECT (Technetium-99m, Thallium-201 Gallium-67, Iodine) and PET (Fluorine-18, Rubidium-82)radioisotopes. Therapeutic radioisotopes cover Beta emitters (Iodine-131, Yttrium-90, Samarium-153, Rhenium-186, Lutetium-177), Alpha Emitters (Radium-223) and Brachytherapy (Cesium-131, Iodine-125, Palladium-103, Iridium-192). By application Industry is segmented into (cardiology, lymphoma, thyroid, neurology oncology, and others). Furthermore, based on geography the Industry is analysed under various regions namely, North America, Europe, Latin America, Asia-Pacific and Middle-East & Africa.
Avail Discount @ http://www.marketdataforecast.com/market-reports/global-nuclear-medicine-radiopharmaceuticals-market-130/request-discount
Key Points from Table of Contents
•Overview
•Executive Summary
•Key Inferences
•New developments
•Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
• Industry Segmentation
o By type
o Therapeutic Radioisotopes
o By application
•Geographical Analysis
•Pipeline Product Analysis
•Strategic Analysis
•PESTLE analysis
•Porter’s Five analysis
•Industry Leaders' Analysis
•Competitive Landscape
Based on Industry share estimation 90 % of the radiopharmaceuticals Industry is dominated by diagnostic radioisotopes while therapeutic radioisotopes contribute 10% of the Industry. The F-18 Industry is mostly contributed by F-18 FDG tracers though this Industry is enriched with future tracers such as F-18 Florbetapir and F-18 Choline. The promising clinical outcome of these tracers has gained the business interest of major research institutes and PET isotope players. Ga-68 and Rb-82 are two other potential isotopes in the PET diagnostic Industry, ensuring high growth of the diagnostics segment. Diagnosis of coronary artery disease, bone metastasis, and Alzheimer’s disease are the most promising indications for the future PET radioisotopes Industry.
Buy now @ https://www.marketdataforecast.com/cart/buy-now/global-nuclear-medicine-radiopharmaceuticals-market-130
North America is the dominant Industry for diagnostic radioisotopes. Within North America, US is the largest consumer Industry for radioisotopes and Canada is the largest producer of Tc-99m. India and China hold a potential Industry for radioisotope due to rising healthcare and increasing demand for different radioisotopes in various treatments and applications.
Some of the key players influencing the global nuclear medicine Industry are GE Healthcare, Hologic Inc., Medix Inc., Segami Corporation,Positron Corporation,Bracco Imaging S.p.A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc. and IBA Molecular Imaging.
About Us:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
Market Data Forecast
Abhishek
+1-888- 702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
